Research progress of concurrent chemoradiation therapy in locally advanced non-small cell lung cancer / 医学研究生学报

ABSTRACT

Lung cancer remains the leading cause of cancer death in the worldwide.Approximately 45% of patients present with stage III disease.For patients with unresectable stage IIIA/B disease,Several clinical trials demonstrated concurrent chemoradiotherapy was superior to TRT alone and sequential chemoradiotherapy.Chemoradiotherapy is a standard treatment for unresectable locally advanced non-small cell lung cancer(NSCLC),Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced NSCLC.Despite a substantial number of clinical trials,The most effective chemotherapy combination,the use of induction or consolidation chemotherapy in addition to the concurrent portion of therapy,and the optimal dose of chemotherapy with concurrent TRT have yet to be determined.In addition to evaluating optimal sequencing strategies of combined modality therapy,current investigations are also focusing on the integration of novel agents,including chemotherapeutic and targeted therapies.Currently ongoing trials involving novel approaches are reviewed here.